Cargando…

Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography

To investigate the fluorescein angiography (FA) findings and compare the extent of retinal vascularization in retinopathy of prematurity (ROP), recovered after intravitreal ranibizumab (IVR) monotherapy and those regressed spontaneously. Infants with a history of ROP who underwent FA between April 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lei, Li, Manhong, Wang, Liang, Yan, Hongxiang, Zhou, Ziyi, Fan, Jing, Zhou, Yi, Gou, Kaili, Guo, Changmei, Wang, Yusheng, Zhang, Zifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651999/
https://www.ncbi.nlm.nih.gov/pubmed/37968276
http://dx.doi.org/10.1038/s41598-023-47212-7
_version_ 1785147663615787008
author Wu, Lei
Li, Manhong
Wang, Liang
Yan, Hongxiang
Zhou, Ziyi
Fan, Jing
Zhou, Yi
Gou, Kaili
Guo, Changmei
Wang, Yusheng
Zhang, Zifeng
author_facet Wu, Lei
Li, Manhong
Wang, Liang
Yan, Hongxiang
Zhou, Ziyi
Fan, Jing
Zhou, Yi
Gou, Kaili
Guo, Changmei
Wang, Yusheng
Zhang, Zifeng
author_sort Wu, Lei
collection PubMed
description To investigate the fluorescein angiography (FA) findings and compare the extent of retinal vascularization in retinopathy of prematurity (ROP), recovered after intravitreal ranibizumab (IVR) monotherapy and those regressed spontaneously. Infants with a history of ROP who underwent FA between April 2018 and November 2021 were retrospectively included. The patients were divided into two groups based on whether they had received IVR (IVR group) or had ROP that regressed spontaneously without treatment (untreated group). The differences between the two groups in zone II ROP were also compared, to equalize the subgroups as much as possible in terms of disease severity. FA findings were recorded. The extent of vascularization was measured by the ratio of the distance from the center of the disk to the border of the vascularized zone (DB) and the distance from the center of the disk to the center of the fovea (DF). The width of the persistent avascular retina (PAR) was counted by disc diameters (DD). One hundred and ten eyes of 55 infants were included in the IVR group and 76 eyes of 38 babies in the untreated group. The ratio of abnormal shape of vessels was significantly higher in the IVR group than in the untreated group (50.9% vs. 35.5%; P = 0.038), while the linear choroidal filling pattern, tortuosity of vessels over the posterior pole, dye leakage, anomalous branching of vessels, circumferential vessels, arteriovenous shunt, abnormal capillary bed, and macular abnormalities were similarly. There was a smaller temporal DB/DF ratio (4.48 vs. 4.63; P = 0.003) and greater PAR (2.63 vs. 1.76; P < 0.001) in the IVR group compared to the untreated group. In zone II ROP, the progression of retinal vascularization was significantly larger in the IVR group than that in the untreated group (P = 0.003), while no statistical differences were observed in FA features, the DB/DF ratio, and PAR between the two subgroups. The residual vascular abnormalities and PAR may be common results of ROP regression. The DB/DF ratio of 4.0 temporally and 3.3 nasally could be used as the preliminary indicators for safe retinal vascularization in the completion of ROP regression.
format Online
Article
Text
id pubmed-10651999
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106519992023-11-15 Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography Wu, Lei Li, Manhong Wang, Liang Yan, Hongxiang Zhou, Ziyi Fan, Jing Zhou, Yi Gou, Kaili Guo, Changmei Wang, Yusheng Zhang, Zifeng Sci Rep Article To investigate the fluorescein angiography (FA) findings and compare the extent of retinal vascularization in retinopathy of prematurity (ROP), recovered after intravitreal ranibizumab (IVR) monotherapy and those regressed spontaneously. Infants with a history of ROP who underwent FA between April 2018 and November 2021 were retrospectively included. The patients were divided into two groups based on whether they had received IVR (IVR group) or had ROP that regressed spontaneously without treatment (untreated group). The differences between the two groups in zone II ROP were also compared, to equalize the subgroups as much as possible in terms of disease severity. FA findings were recorded. The extent of vascularization was measured by the ratio of the distance from the center of the disk to the border of the vascularized zone (DB) and the distance from the center of the disk to the center of the fovea (DF). The width of the persistent avascular retina (PAR) was counted by disc diameters (DD). One hundred and ten eyes of 55 infants were included in the IVR group and 76 eyes of 38 babies in the untreated group. The ratio of abnormal shape of vessels was significantly higher in the IVR group than in the untreated group (50.9% vs. 35.5%; P = 0.038), while the linear choroidal filling pattern, tortuosity of vessels over the posterior pole, dye leakage, anomalous branching of vessels, circumferential vessels, arteriovenous shunt, abnormal capillary bed, and macular abnormalities were similarly. There was a smaller temporal DB/DF ratio (4.48 vs. 4.63; P = 0.003) and greater PAR (2.63 vs. 1.76; P < 0.001) in the IVR group compared to the untreated group. In zone II ROP, the progression of retinal vascularization was significantly larger in the IVR group than that in the untreated group (P = 0.003), while no statistical differences were observed in FA features, the DB/DF ratio, and PAR between the two subgroups. The residual vascular abnormalities and PAR may be common results of ROP regression. The DB/DF ratio of 4.0 temporally and 3.3 nasally could be used as the preliminary indicators for safe retinal vascularization in the completion of ROP regression. Nature Publishing Group UK 2023-11-15 /pmc/articles/PMC10651999/ /pubmed/37968276 http://dx.doi.org/10.1038/s41598-023-47212-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wu, Lei
Li, Manhong
Wang, Liang
Yan, Hongxiang
Zhou, Ziyi
Fan, Jing
Zhou, Yi
Gou, Kaili
Guo, Changmei
Wang, Yusheng
Zhang, Zifeng
Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
title Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
title_full Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
title_fullStr Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
title_full_unstemmed Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
title_short Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
title_sort evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651999/
https://www.ncbi.nlm.nih.gov/pubmed/37968276
http://dx.doi.org/10.1038/s41598-023-47212-7
work_keys_str_mv AT wulei evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT limanhong evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT wangliang evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT yanhongxiang evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT zhouziyi evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT fanjing evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT zhouyi evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT goukaili evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT guochangmei evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT wangyusheng evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography
AT zhangzifeng evaluationofretinalvascularizationinretinopathyofprematurityregressedafterintravitrealranibizumabmonotherapyorwithouttreatmentbasedonfluoresceinangiography